Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

A New Immunotherapy Method in Cancer Treatment: The Anti-GARP Antibody

A New Immunotherapy Method in Cancer Treatment: The Anti-GARP Antibody

According to a study published in Nature Communications on September 11, 2020, scientists successfully neutralized a molecule that prevents the immune system from acting against cancer, called GARP. The research team also discovered that this method enhanced the effect of another well-known immunotherapy that is not always effective in every cancer type, and enabled the tumor to regress.

Cancer immunotherapy is a treatment method that triggers the body’s naturally occurring immune responses to attack tumor cells. These responses are often suppressed by various cells or molecules, making it easier for tumor cells to escape the immune system and grow. This is one of the most frequently encountered situations in cancer treatment and adversely affects treatment response.

In 2004, Prof. Sophie Lucas began to study the tumor microenvironment by investigating the function of the immunosuppressive cells frequently observed there. The aim of the study was to identify and eliminate suppressive cells, thereby enabling antibodies to act against tumor cells. The experiments identified the cell group found at high concentrations in patients with cancer that causes suppression of the immune system: regulatory T lymphocytes (Treg).

Continuing her work on this subject, Prof. Lucas succeeded in identifying the function of a molecule displayed on the surface of regulatory T lymphocytes in 2018. GARP is the name of this molecule, which acts as a messenger for regulatory T lymphocytes, sending immune-suppressing signals. The team then developed an antibody that binds to GARP and prevents it from sending signals: the anti-GARP antibody.

The team’s first test results were published in August 2020. According to the results of this highly exciting study, in experiments using animal models, anti-GARP antibodies inhibited the activity of regulatory T lymphocytes. This creates an immune response against tumor cells and destroys them. The effectiveness of the anti-GARP antibody was also investigated in combination with anti-PD1 antibodies, which have proven effectiveness and are used in certain cancer types. Combining immunotherapy methods that trigger immune system activity through two different mechanisms increased the effectiveness of cancer treatment. 

This new method, which is at the preclinical research stage, is extremely important for the future. Conducting the same tests in humans may provide a more effective treatment in the fight against cancer.

Sources

Grégoire de Streel; Charlotte Bertrand; Nicolas Chalon et al.
Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer.
Nature Communications, 11 Sep 2020.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

A New Immunotherapy Method in Cancer Treatment: The Anti-GARP Antibody

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy